MARKET

VYNT

VYNT

Vyant Bio Inc
NASDAQ
0.5580
+0.0046
+0.83%
After Hours: 0.5600 +0.002 +0.36% 17:43 09/30 EDT
OPEN
0.5524
PREV CLOSE
0.5534
HIGH
0.5712
LOW
0.5524
VOLUME
23.30K
TURNOVER
0
52 WEEK HIGH
3.240
52 WEEK LOW
0.5000
MARKET CAP
16.37M
P/E (TTM)
0.4172
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers
Benzinga · 4d ago
Looking Into Vyant Bio's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Vyant Bio's (NASDAQ:VYNT) reported sales totaled $165 thousand. Despite a 36.65% increase in earnings, the company posted a loss of $5.80 million.
Benzinga · 09/13 14:01
Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022
-Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Co...
GlobeNewswire · 09/01 12:00
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s p...
GlobeNewswire · 08/31 12:00
BRIEF-Vyant Bio Reports Second Quarter And First Half 2022 Results
BRIEF-Vyant Bio Reports Second Quarter And First Half 2022 Results
Reuters · 08/22 20:38
Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M
Vyant Bio press release (<span class="ticker-hover...
Seekingalpha · 08/22 20:12
Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance...
GlobeNewswire · 08/22 20:10
Earnings Scheduled For August 22, 2022
  Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is estimated to report quarterly loss at $0.22 per share on revenue of $3.10 million.
Benzinga · 08/22 09:19
More
About VYNT
Vyant Bio, Inc. (Vyant Bio) is a biotechnology drug discovery company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio is also focused on combining sophisticated data science capabilities with highly functional human cell derived disease models. Vyant Bio’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. Vyant Bio’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinsons Disease (PD).

Webull offers kinds of Vyant Bio Inc stock information, including NASDAQ:VYNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYNT stock methods without spending real money on the virtual paper trading platform.